Rabies vaccine prepared from the virus grown in Japanese quail embryo cell cultures.
Fixed rabies virus strain MNIIVP-74 was grown in Japanese quail embryo cell cultures, concentrated by ultrafiltration and inactivated with beta-propiolactone. The resulting vaccine was markedly antigenic and immunogenic for laboratory animals. Human volunteers injected with 2.0 ml vaccine on days 0, 3, 7, 14, 30 and 90 exhibited more intensive and longer antibody production than those injected daily for 14 days.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002478:Cells, Cultured; D003370:Coturnix; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D011420:Propiolactone; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011820:Rabies virus / Q000254:growth & development / Q000276:immunology; D013997:Time Factors; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014776:Virus Cultivation
D000914:Antibodies, Viral; D011819:Rabies Vaccines; D014613:Vaccines, Attenuated; D011420:Propiolactone